Cargando…
Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xenobiotics. Glutathione pegylated liposomal doxorub...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885379/ https://www.ncbi.nlm.nih.gov/pubmed/24416140 http://dx.doi.org/10.1371/journal.pone.0082331 |
_version_ | 1782298736112697344 |
---|---|
author | Gaillard, Pieter J. Appeldoorn, Chantal C. M. Dorland, Rick van Kregten, Joan Manca, Francesca Vugts, Danielle J. Windhorst, Bert van Dongen, Guus A. M. S. de Vries, Helga E. Maussang, David van Tellingen, Olaf |
author_facet | Gaillard, Pieter J. Appeldoorn, Chantal C. M. Dorland, Rick van Kregten, Joan Manca, Francesca Vugts, Danielle J. Windhorst, Bert van Dongen, Guus A. M. S. de Vries, Helga E. Maussang, David van Tellingen, Olaf |
author_sort | Gaillard, Pieter J. |
collection | PubMed |
description | Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xenobiotics. Glutathione pegylated liposomal doxorubicin (2B3-101) is being developed as a new treatment option for patients with brain cancer. It is based on already marketed pegylated liposomal doxorubicin (Doxil®/Caelyx®), with an additional glutathione coating that safely enhances drug delivery across the BBB. Uptake of 2B3-101 by human brain capillary endothelial cells in vitro was time-, concentration- and temperature-dependent, while pegylated liposomal doxorubicin mainly remained bound to the cells. In vivo, 2B3-101 and pegylated liposomal doxorubicin had a comparable plasma exposure in mice, yet brain retention 4 days after administration was higher for 2B3-101. 2B3-101 was overall well tolerated by athymic FVB mice with experimental human glioblastoma (luciferase transfected U87MG). In 2 independent experiments a strong inhibition of brain tumor growth was observed for 2B3-101 as measured by bioluminescence intensity. The effect of weekly administration of 5 mg/kg 2B3-101 was more pronounced compared to pegylated liposomal doxorubicin (p<0.05) and saline (p<0.01). Two out of 9 animals receiving 2B3-101 showed a complete tumor regression. Twice-weekly injections of 5 mg/kg 2B3-101 again had a significant effect in inhibiting brain tumor growth (p<0.001) compared to pegylated liposomal doxorubicin and saline, and a complete regression was observed in 1 animal treated with 2B3-101. In addition, twice-weekly dosing of 2B3-101 significantly increased the median survival time by 38.5% (p<0.001) and 16.1% (p<0.05) compared to saline and pegylated liposomal doxorubicin, respectively. Overall, these data demonstrate that glutathione pegylated liposomal doxorubicin enhances the effective delivery of doxorubicin to brain tumors and could become a promising new therapeutic option for the treatment of brain malignancies. |
format | Online Article Text |
id | pubmed-3885379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38853792014-01-10 Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) Gaillard, Pieter J. Appeldoorn, Chantal C. M. Dorland, Rick van Kregten, Joan Manca, Francesca Vugts, Danielle J. Windhorst, Bert van Dongen, Guus A. M. S. de Vries, Helga E. Maussang, David van Tellingen, Olaf PLoS One Research Article Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xenobiotics. Glutathione pegylated liposomal doxorubicin (2B3-101) is being developed as a new treatment option for patients with brain cancer. It is based on already marketed pegylated liposomal doxorubicin (Doxil®/Caelyx®), with an additional glutathione coating that safely enhances drug delivery across the BBB. Uptake of 2B3-101 by human brain capillary endothelial cells in vitro was time-, concentration- and temperature-dependent, while pegylated liposomal doxorubicin mainly remained bound to the cells. In vivo, 2B3-101 and pegylated liposomal doxorubicin had a comparable plasma exposure in mice, yet brain retention 4 days after administration was higher for 2B3-101. 2B3-101 was overall well tolerated by athymic FVB mice with experimental human glioblastoma (luciferase transfected U87MG). In 2 independent experiments a strong inhibition of brain tumor growth was observed for 2B3-101 as measured by bioluminescence intensity. The effect of weekly administration of 5 mg/kg 2B3-101 was more pronounced compared to pegylated liposomal doxorubicin (p<0.05) and saline (p<0.01). Two out of 9 animals receiving 2B3-101 showed a complete tumor regression. Twice-weekly injections of 5 mg/kg 2B3-101 again had a significant effect in inhibiting brain tumor growth (p<0.001) compared to pegylated liposomal doxorubicin and saline, and a complete regression was observed in 1 animal treated with 2B3-101. In addition, twice-weekly dosing of 2B3-101 significantly increased the median survival time by 38.5% (p<0.001) and 16.1% (p<0.05) compared to saline and pegylated liposomal doxorubicin, respectively. Overall, these data demonstrate that glutathione pegylated liposomal doxorubicin enhances the effective delivery of doxorubicin to brain tumors and could become a promising new therapeutic option for the treatment of brain malignancies. Public Library of Science 2014-01-08 /pmc/articles/PMC3885379/ /pubmed/24416140 http://dx.doi.org/10.1371/journal.pone.0082331 Text en © 2014 Gaillard et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Gaillard, Pieter J. Appeldoorn, Chantal C. M. Dorland, Rick van Kregten, Joan Manca, Francesca Vugts, Danielle J. Windhorst, Bert van Dongen, Guus A. M. S. de Vries, Helga E. Maussang, David van Tellingen, Olaf Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title_full | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title_fullStr | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title_full_unstemmed | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title_short | Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) |
title_sort | pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2b3-101) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885379/ https://www.ncbi.nlm.nih.gov/pubmed/24416140 http://dx.doi.org/10.1371/journal.pone.0082331 |
work_keys_str_mv | AT gaillardpieterj pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT appeldoornchantalcm pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT dorlandrick pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT vankregtenjoan pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT mancafrancesca pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT vugtsdaniellej pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT windhorstbert pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT vandongenguusams pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT devrieshelgae pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT maussangdavid pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 AT vantellingenolaf pharmacokineticsbraindeliveryandefficacyinbraintumorbearingmiceofglutathionepegylatedliposomaldoxorubicin2b3101 |